Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGS - Nasdaq Real Time Price USD

Incyte Corporation (INCY)

Compare

60.91

+0.36

+(0.59%)

At close: April 1 at 4:00:01 PM EDT

62.00

+1.09

+(1.79%)

Pre-Market: 4:17:29 AM EDT

3 Reasons INCY is Risky and 1 Stock to Buy Instead

Over the past six months, Incyte’s shares (currently trading at $60.02) have posted a disappointing 11.8% loss while the S&P 500 was down 1.7%. This was partly driven by its softer quarterly results and might have investors contemplating their next move.

StockStory 23 hours ago

INCY
+0.59%
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico

MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. Minjuvi® in combination with lenalidomide, followed by Minjuvi® monotherapy, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are not eligible for autolo

GlobeNewswire 6 days ago

KHTRF

INCY
+0.59%
Why Incyte Stock Was Tanking This Week

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock over the past few days. On Monday, Incyte published the top-line results from two phase 3 trials of its povorcitinib, a treatment aimed at combating moderate to severe hidradenitis suppurativa (HS), also known as acne inversa. In each of the trials, the drug met its primary endpoint of a significant (50%-plus) reduction from baseline in abscess and inflammatory nodule count versus a placebo, with no advances in abscess or draining tunnel count.

Motley Fool 11 days ago

INCY
+0.59%
1 Healthcare Stock on Our Watchlist and 2 to Brush Off

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 9.1%. This drop was worse than the S&P 500’s 1.8% loss.

StockStory 11 days ago

INCY
+0.59%
UFPT
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics

Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics are included in this Analyst Blog.

Zacks 12 days ago

SRPT
-2.99%
VTVT

GILD
Incyte Had a Bad Week. Investors Are Used to It.

Incyte tumbled more than 8% earlier this week after disappointing Phase 3 study results for povorcitinib, a drug that targets severe hidradenitis suppurativa (HS). RBC Capital Markets analyst Brian Abrahams warned after the results that sales will almost certainly miss the expected $1 billion mark. Another analyst, Truist Securities’ Srikripa Devarakonda, noted that HS is a disease that tends to cause variable symptoms in people that respond differently to treatment.

Barrons.com 12 days ago

INCY
+0.59%
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More

SRPT and INCY are in the spotlight this week following a report of an adverse event and study data, respectively.

Zacks 12 days ago

SRPT
-2.99%
INCY
+0.59%
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers.

StockStory 12 days ago

NTRA

EXAS

INCY
+0.59%
Incyte price target lowered to $72 from $74 at Truist

Truist lowered the firm’s price target on Incyte (INCY) to $72 from $74 and keeps a Hold rating on the shares. Following the povorcitinib/povo Phase3 results in moderate to severe hidradenitis suppurativa, HS, the firm believes that the data were statistically significant but missed expectations on magnitude of benefit, adding that it sees povo as “modestly competitive”, the analyst tells investors in a research note. The firm adds that its updated model reflects povo as a second-line opportunit

TipRanks 13 days ago

INCY
+0.59%
INCY Stock Down on Disappointing Skin Disease Study Data

Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.

Zacks 14 days ago

INCY
+0.59%
Stoke CEO exits; Medicare drug price talks advance

Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers targeted for second round of Medicare price talks agreed to participate.

BioPharma Dive 14 days ago

STOK

INCY
+0.59%
AZN
Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Incyte Corporation (NASDAQ:INCY) stands against other best biotech stocks. Although biotech stocks had a “challenging” year in 2024, JPMorgan believes that some of the industry’s companies could […]

Insider Monkey 14 days ago

INCY
+0.59%
Incyte stock dives after drug trial disappoints investors

Incyte (INCY) shares are sinking after its third phase results for Povorcitinib, a drug for chronic skin disease, were less promising than those from earlier trials. Yahoo Finance Senior Reporter Anjalee Khemlani outlines the details on Market Domination. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Yahoo Finance Video 15 days ago

INCY
+0.59%
S&P 500 Gains and Losses Today: Index Ticks Higher Ahead of This Week's Fed Decision

The S&P 500 edged up 0.6% on Monday, March 17, after a report showed retail sales recovered in February but fell short of expectations.

Investopedia 15 days ago

^GSPC

INTC

INCY
+0.59%
Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'

Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock fell.

Investor's Business Daily 15 days ago

INCY
+0.59%
Oil pressures, Robinhood, Incyte: Market Minute

Yahoo Finance host Julie Hyman is tracking some of the biggest stock stories in this Market Minute, including Red Sea tensions pressuring oil prices (CL=F, BZ=F), the launch of Robinhood Markets' (HOOD) prediction markets hub, and Incyte's (INCY) Phase 3 trial data on a skin condition treatment. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Yahoo Finance Video 15 days ago

CL=F

HOOD

BZ=F
Top Midday Decliners

Affirm (AFRM) retreated Monday after CNBC reported retailer Walmart (WMT) plans to select rival Swed

PREMIUM
MT Newswires 15 days ago

TSLA

INCY
+0.59%
WMT
Why Incyte (INCY) Stock Is Nosediving

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment, which fell below Wall Street's expectations. According to the data, the drug was effective for less than half of the participants who took it in the trials.

StockStory 15 days ago

INCY
+0.59%
Incyte stock hit by 11% despite paediatric dermatology trials hitting target

The US company’s two simultaneous trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

Clinical Trials Arena 15 days ago

INCY
+0.59%
GLDAF
Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results

Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.

Investopedia 15 days ago

INCY
+0.59%
^GSPC

Performance Overview

Return	INCY	S&P 500 (^GSPC)
YTD	-11.81%	-4.23%
1-Year	+7.54%	+7.42%
3-Year	-23.81%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Incyte Corporation (INCY)

3 Reasons INCY is Risky and 1 Stock to Buy Instead

Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico

Why Incyte Stock Was Tanking This Week

1 Healthcare Stock on Our Watchlist and 2 to Brush Off

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics

Incyte Had a Bad Week. Investors Are Used to It.

Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

Incyte price target lowered to $72 from $74 at Truist

INCY Stock Down on Disappointing Skin Disease Study Data

Stoke CEO exits; Medicare drug price talks advance

Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires

Incyte stock dives after drug trial disappoints investors

S&P 500 Gains and Losses Today: Index Ticks Higher Ahead of This Week's Fed Decision

Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'

Oil pressures, Robinhood, Incyte: Market Minute

Top Midday Decliners

Why Incyte (INCY) Stock Is Nosediving

Incyte stock hit by 11% despite paediatric dermatology trials hitting target

Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results

Performance Overview